Literature DB >> 3544642

Positive-pressure ventilation at moderately high frequency in newborn infants with respiratory distress syndrome (IRDS).

G Sedin.   

Abstract

In 24 seriously ill newborn infants with respiratory distress syndrome (IRDS) and ensuing respiratory failure, high-frequency positive-pressure ventilation was administered. The mean gestational age of the infants was 32 +/- 3 weeks. In the infant ventilator employed, the compressible volume had been reduced in order to give higher flow rates but lower intratracheal pressures. The ventilation frequency was kept constant at 60-66 per min and the insufflation period at 32-35% of the ventilatory cycle. A positive end-expiratory pressure (PEEP) of 0.2-0.6 kPa was used. Arterial PCO2 was maintained at 4.0-5.3 kPa and PO2 at 8.5-10.5 kPa by adjusting the gas flow through the patient circuit, the peak tubing pressure, the PEEP and the oxygen concentration in inspired gas. High-frequency positive-pressure ventilation improved oxygenation and gave adequate alveolar ventilation in all infants, in most cases at a low peak pressure. Only one infant developed pneumothorax during intermittent positive pressure ventilation, and in no infant did bronchopulmonary dysplasia or retrolental fibroplasia occur. One infant died from intracranial hemorrhage during the ventilation period, giving a survival rate of 96%.

Entities:  

Mesh:

Year:  1986        PMID: 3544642     DOI: 10.1111/j.1399-6576.1986.tb02467.x

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  2 in total

1.  [Indirect determination of the intrapulmonary pressure course in the lung model in high frequency ventilation].

Authors:  W Hultzsch; G Lipowsky
Journal:  Klin Wochenschr       Date:  1989-09-15

2.  Multicentre randomised controlled trial of high against low frequency positive pressure ventilation. Oxford Region Controlled Trial of Artificial Ventilation OCTAVE Study Group.

Authors: 
Journal:  Arch Dis Child       Date:  1991-07       Impact factor: 3.791

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.